Market Place
Sourcing Support
Oncolytics Aligns With FDA on Planned Pivotal Anal Cancer Study
27 Apr 2026 //
FIRSTWORD PHARMA
Oncolytics Schedules FDA Meeting on Pelareorep in Anal Cancer
06 Apr 2026 //
GLOBENEWSWIRE
Oncolytics Biotech Completes Domicile Change to the United States
01 Apr 2026 //
GLOBENEWSWIRE
Oncolytics Unveils Pelareorep Immune-Priming Data at AACR 2026
19 Mar 2026 //
GLOBENEWSWIRE
Oncolytics Biotech Launches Randomized Colorectal Cancer Study
02 Mar 2026 //
GLOBENEWSWIRE
Oncolytics Biotech Prioritizes Anal, Colorectal Cancer Programs
24 Feb 2026 //
GLOBENEWSWIRE
Oncolytics Gets FDA Fast Track for Pelareorep in KRAS mCRC Cancer
04 Feb 2026 //
GLOBENEWSWIRE
How 2026`s Clinical Leaders Are Beating Cancer Benchmarks
27 Jan 2026 //
PR NEWSWIRE
Oncolytics Biotech Reveals Shareholders` Meeting Outcome
15 Jan 2026 //
GLOBENEWSWIRE
Oncolytics Bio Names McAdory as EVP, Yujun Wu as Biostats Lead
14 Jan 2026 //
GLOBENEWSWIRE
Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy
12 Jan 2026 //
GLOBENEWSWIRE
Oncolytics Biotech Details Move To Nevada For Strategic Reasons
09 Jan 2026 //
GLOBENEWSWIRE
Oncolytics Biotech Updates Intellectual Property Strategy
08 Jan 2026 //
PHARMIWEB
Oncolytics Biotech Expands Gastrointestinal Tumor Advisory Board
07 Jan 2026 //
BUSINESSWIRE
Oncolytics Biotech Announces Pelareorep Data in KRAS-Mutant
16 Dec 2025 //
BUSINESSWIRE
Oncolytics Biotech Reschedules Nevada Reincorporation Meeting
09 Dec 2025 //
BUSINESSWIRE
Oncolytics Biotech Updates Shareholders On Special Meeting
20 Nov 2025 //
BUSINESSWIRE
Oncolytics Biotech Aligns With FDA On Pelareorep Study
19 Nov 2025 //
BUSINESSWIRE
Oncolytics Biotech Forms Gi Tumor Advisory Board For Pelareorep
04 Nov 2025 //
BUSINESSWIRE
Oncolytics Biotech Files Prospectus For Shareholders` Meeting
20 Oct 2025 //
PR NEWSWIRE
Oncolytics Biotech Updates First-Line Pancreatic Cancer Study
29 Sep 2025 //
PR NEWSWIRE
Oncolytics Biotech® Updates Safety Data for Pelareorep
02 Sep 2025 //
PR NEWSWIRE
Oncolytics Biotech® to Present at Investor Conferences
28 Aug 2025 //
PR NEWSWIRE
Oncolytics Biotech® Reveals Annual General Meeting Voting Results
11 Aug 2025 //
PR NEWSWIRE
Oncolytics Bio Voluntarily Delists from Toronto Stock Exchange
08 Aug 2025 //
PR NEWSWIRE
Oncolytics Biotech to Reveal Second Quarter Financial Results
06 Aug 2025 //
PR NEWSWIRE
Oncolytics Bio to Initiate FDA-Approved Pancreatic Cancer Study
29 Jul 2025 //
PR NEWSWIRE
Event Spotlights Pelareorep GI, Pancreatic Cancer Data
23 Jul 2025 //
PR NEWSWIRE
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
22 Jul 2025 //
PR NEWSWIRE
Oncolytics Biotech® Shows Pelareorep in Various Tumor Types
16 Jul 2025 //
PR NEWSWIRE
Oncolytics Hosts KOL Talk on GI and Pancreatic Cancers
11 Jul 2025 //
PR NEWSWIRE
Oncolytics Highlights Pelareorep Data, Study Commitment
09 Jul 2025 //
PR NEWSWIRE
Public Cancer Funding Wanes, Industry Leads Oncology Breakthrough
12 Jun 2025 //
PR NEWSWIRE
Oncolytics to Present Pelareorep Trial Data at ASCO
23 May 2025 //
PR NEWSWIRE
Oncolytics Pelareorep Asco Abstracts: Pancreatic Moa Immunotherapy Potential
24 May 2024 //
PR NEWSWIRE
Oncolytics Biotech Announces AGM Voting Results
16 May 2024 //
PR NEWSWIRE
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
14 Feb 2024 //
PR NEWSWIRE
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
09 Jan 2024 //
PR NEWSWIRE
Oncolytics Announces Phase 1/2 Study of Pelareorep Has Met Criteria for Efficacy
09 Nov 2023 //
PR NEWSWIRE
Oncolytics and SOLTI Present Further Positive Pelareorep Translational Data
03 Nov 2023 //
PR NEWSWIRE
Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units
31 Jul 2023 //
PR NEWSWIRE
Oncolytics Biotech to Host Conference to Discuss First Quarter Financial Results
12 Apr 2023 //
PR NEWSWIRE
